Portal de Periódicos da CAPES

The Effects of Long-term Food Oral Immunotherapy on Compliance, Quality of Life, and Perceived Burden of Care

2023; Elsevier BV; Volume: 151; Issue: 2 Linguagem: Inglês

10.1016/j.jaci.2022.12.092

1097-6825

Jyothi Tirumalasetty, Liv Sullivan, Kristine Martinez, William Collins, Marleni Albarran, Pooja Gajare, Laurie Kost, R. Sharon Chinthrajah, Sayantani Sindher, Shu Cao,

Education and Learning Interventions

The safety and efficacy of food oral immunotherapy (OIT) has been extensively studied, however long-term maintenance OIT studies are limited. To better understand the durability of OIT long-term, larger studies on compliance, quality of life (QOL), and burden of treatment (BOT) are needed. Participants and caregivers who participated in food OIT clinical trials at Stanford University completed three IRB approved surveys: food allergy long-term follow up questionnaire (FALTFU), food allergy quality of life questionnaire (FAQOL), and burden of treatment questionnaire (BOT). FAQOL scores at baseline and study completion were compared using a Wilcoxon signed rank test. BOT was measured on a 1 to 7 scale (1=extremely positive, 7=extremely negative). 186 participants completed FALTFU questionnaires. 120 (69%) were children (0-12 years). Compliance rates were 79% for multi-food OIT (n=77) and 61% for single-food OIT (n=109, p=0.016). Younger children (0-12 years) were more compliant vs older children and adults (80% vs 52%, p<0.001). 104 (65%) continued peanut, 40 (78%) continued cashew, and 36 (69%) continued walnut. Multi-food OIT participants reported worse baseline FAQOL vs single-food OIT participants (p=0.034). Multi-food OIT participants reported significant improvement of FAQOL after study completion (p<0.001) but single-food OIT participants did not (p=0.055). Younger children reported positive or extremely positive more frequently on BOT vs older children and adults (82% vs 57%, p=0.001). This is the largest, long-term OIT follow up study to date to assess compliance, QOL, and BOT. The majority of participants continued OIT long-term. Positive treatment perception and improved QOL were seen among all participants.